Survival period of breast cancer single bone metastasis is long, after bone metastasis occurs, systemic systemic therapy should be the main treatment, and categorized according to breast cancer typing: for hormone receptor-positive and HER2-negative patients, priority is given to endocrine therapy (commonly known as anastrozole, letrozole, exemestane, fulvestrant, etc.); for triple-negative patients, if there is no metastasis to other organs, priority is given to single-agent chemotherapy (e.g., paclitaxel , vincristine, capecitabine, etc.), and if there are other organ metastases at the same time and rapid remission is needed, priority will be given to combination chemotherapy; for HER2-positive patients, consider anti-HER2 treatment regimens (e.g. chemotherapy combined with trastuzumab, etc.). Also give bisphosphonate therapy (e.g. zoledronic acid, etc.). If bone destruction is severe and weight-bearing bone stability is poor, consider orthopedic surgery or local radiation therapy. Bone metastases require long-term treatment, and long-term maintenance therapy is still needed after first-line treatment is effective.